WO2002070010A1 - Inhibiteurs de rejet du greffon - Google Patents

Inhibiteurs de rejet du greffon Download PDF

Info

Publication number
WO2002070010A1
WO2002070010A1 PCT/JP2002/000930 JP0200930W WO02070010A1 WO 2002070010 A1 WO2002070010 A1 WO 2002070010A1 JP 0200930 W JP0200930 W JP 0200930W WO 02070010 A1 WO02070010 A1 WO 02070010A1
Authority
WO
WIPO (PCT)
Prior art keywords
graft rejection
ailim
organs
rejection inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/000930
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
Seiichi Suzuki
Mitsuaki Isobe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HK03105544.7A priority Critical patent/HK1053266B/xx
Priority to HU0303332A priority patent/HU228045B1/hu
Priority to CA002439858A priority patent/CA2439858C/en
Priority to SK1214-2003A priority patent/SK288048B6/sk
Priority to EP02710508A priority patent/EP1374901B9/en
Priority to IL15684502A priority patent/IL156845A0/xx
Priority to BR0207787-6A priority patent/BR0207787A/pt
Priority to AU2002228435A priority patent/AU2002228435B2/en
Priority to RU2003129166/15A priority patent/RU2263512C2/ru
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Priority to NZ527076A priority patent/NZ527076A/xx
Priority to HK04104524.3A priority patent/HK1061531B/en
Priority to DE60217839T priority patent/DE60217839T2/de
Priority to CN028058054A priority patent/CN1518458B/zh
Priority to MXPA03006736A priority patent/MXPA03006736A/es
Priority to KR1020037011255A priority patent/KR100609444B1/ko
Publication of WO2002070010A1 publication Critical patent/WO2002070010A1/ja
Priority to IL156845A priority patent/IL156845A/en
Priority to NO20033839A priority patent/NO331690B1/no
Anticipated expiration legal-status Critical
Priority to US10/793,171 priority patent/US7438905B2/en
Priority to US12/209,643 priority patent/US20090047292A1/en
Priority to NO20110218A priority patent/NO20110218L/no
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Graft Or Block Polymers (AREA)
  • External Artificial Organs (AREA)
  • Transplanting Machines (AREA)
  • Soil Working Implements (AREA)
  • Cylinder Crankcases Of Internal Combustion Engines (AREA)
PCT/JP2002/000930 1999-12-10 2002-02-05 Inhibiteurs de rejet du greffon Ceased WO2002070010A1 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
HK03105544.7A HK1053266B (en) 1999-12-10 2000-12-08 Pharmaceutical combinations and their use in treating gastrointestinal disorders
HK04104524.3A HK1061531B (en) 2001-03-01 2002-02-05 Graft rejection suppressors
SK1214-2003A SK288048B6 (sk) 2001-03-01 2002-02-05 Use of a substance effective in modulating signal transduction mediated by AILIM for suppressing, treating or preventing graft rejection and pharmaceutical composition comprising the substance for use in suppressing, treating or preventing graft rejection
EP02710508A EP1374901B9 (en) 2001-03-01 2002-02-05 Graft rejection suppressors
IL15684502A IL156845A0 (en) 2001-03-01 2002-02-05 Graft rejection suppressors
BR0207787-6A BR0207787A (pt) 2001-03-01 2002-02-05 Supressores de rejeição de enxertos
AU2002228435A AU2002228435B2 (en) 2001-03-01 2002-02-05 Graft rejection inhibitors
CN028058054A CN1518458B (zh) 2001-03-01 2002-02-05 移植物排斥反应抑制剂
CA002439858A CA2439858C (en) 2001-03-01 2002-02-05 Graft rejection suppressors
NZ527076A NZ527076A (en) 2001-03-01 2002-02-05 Graft rejection inhibitors used in combination with immunosuppressants
DE60217839T DE60217839T2 (de) 2001-03-01 2002-02-05 Mittel zur suppression von transplantat-abstossung
HU0303332A HU228045B1 (en) 2001-03-01 2002-02-05 Graft rejection suppressing agents
RU2003129166/15A RU2263512C2 (ru) 2001-03-01 2002-02-05 Средства, подавляющие отторжение трансплантата
MXPA03006736A MXPA03006736A (es) 2001-03-01 2002-02-05 Supresores del rechazamiento de injerto.
KR1020037011255A KR100609444B1 (ko) 2001-03-01 2002-02-05 이식편 거절반응 억제제
IL156845A IL156845A (en) 2001-03-01 2003-07-09 Use of substances that affect the activity of AILIM for the preparation of a drug to prevent implant rejection
NO20033839A NO331690B1 (no) 2001-03-01 2003-08-29 Forbindelse, og farmasoytisk kombinasjon av forbindelse, som har en aktivitet til a modulere signaloverforing formidlet av AILIM for forsterkning av virkningen av immunsupprimerende midler pa undertrykkelse, behandling eller forebyggelse av transplantatavstotning ved transplantasjon av et organ, del av et organ eller et vev.
US10/793,171 US7438905B2 (en) 2001-03-01 2004-03-04 Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM
US12/209,643 US20090047292A1 (en) 2001-03-01 2008-09-12 Graft rejection suppressors
NO20110218A NO20110218L (no) 2001-03-01 2011-02-08 Transplantatrejeksjonssuppressorer

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2001056216 2001-03-01
JP2001-56216 2001-03-01
JP2001056209 2001-03-01
JP2001-56209 2001-03-01
JP2002008028 2002-01-16
JP2002-8028 2002-01-16

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10451972 A-371-Of-International 2002-02-05
US10/793,171 Continuation-In-Part US7438905B2 (en) 2001-03-01 2004-03-04 Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM

Publications (1)

Publication Number Publication Date
WO2002070010A1 true WO2002070010A1 (fr) 2002-09-12

Family

ID=27346134

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/000930 Ceased WO2002070010A1 (fr) 1999-12-10 2002-02-05 Inhibiteurs de rejet du greffon

Country Status (24)

Country Link
US (2) US7438905B2 (https=)
EP (2) EP1769807B1 (https=)
JP (1) JP4212278B2 (https=)
KR (1) KR100609444B1 (https=)
CN (1) CN1518458B (https=)
AT (2) ATE352318T1 (https=)
AU (1) AU2002228435B2 (https=)
BR (1) BR0207787A (https=)
CA (1) CA2439858C (https=)
CY (1) CY1110143T1 (https=)
CZ (1) CZ20032406A3 (https=)
DE (2) DE60235928D1 (https=)
DK (1) DK1769807T3 (https=)
ES (1) ES2344219T3 (https=)
HU (2) HU228045B1 (https=)
IL (2) IL156845A0 (https=)
MX (1) MXPA03006736A (https=)
NO (2) NO331690B1 (https=)
NZ (1) NZ527076A (https=)
PT (1) PT1769807E (https=)
RU (1) RU2263512C2 (https=)
SI (1) SI1769807T1 (https=)
SK (1) SK288048B6 (https=)
WO (1) WO2002070010A1 (https=)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803039B2 (en) 2000-05-18 2004-10-12 Japan Tobacco Inc. Human monoclonal antibody against a costimulatory signal transduction molecule AILIM
US7030225B1 (en) 1997-02-27 2006-04-18 Japan Tobacco, Inc. Antibodies to JTT-1 protein, cells secreting such antibodies, and methods of making such antibodies
US7045615B2 (en) 1997-02-27 2006-05-16 Japan Tobacco, Inc. Nucleic acids encoding JTT-1 protein
US7438905B2 (en) 2001-03-01 2008-10-21 Japan Tobacco, Inc. Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM
US7465444B2 (en) 2001-03-27 2008-12-16 Japan Tobacco, Inc. Methods of suppressing or treating an inflammatory bowel disease by administering an antibody or portion thereof that binds to AILIM
US7465445B2 (en) 1999-08-30 2008-12-16 Japan Tobacco Inc. Methods of preventing or treating graft versus host reaction by administering an antibody or portion thereof that binds to AILIM
WO2017220990A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
WO2019122884A1 (en) 2017-12-19 2019-06-27 Kymab Limited Antibodies to icos
WO2021229032A1 (en) 2020-05-14 2021-11-18 Kymab Limited Tumour biomarkers for immunotherapy
WO2022243378A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
WO2022254227A1 (en) 2021-06-04 2022-12-08 Kymab Limited Treatment of pd-l1 negative or low expressing cancer with anti-icos antibodies
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies
RU2833126C2 (ru) * 2022-11-15 2025-01-14 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр гематологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ гематологии" Минздрава России) Способ профилактики несостоятельности трансплантата аллогенного костного мозга или гемопоэтических стволовых клеток при наличии у реципиента донор-специфичных анти-HLA антител

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
CN1411373A (zh) * 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
RU2291675C2 (ru) * 2004-07-09 2007-01-20 Институт теоретической и экспериментальной биофизики РАН Способ обработки трансплантатов для сердечно-сосудистой хирургии
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds
JP2006321765A (ja) * 2005-05-20 2006-11-30 Mikiko Ueda 肝移植における拒絶反応の予防又は治療薬、或いは拒絶反応とは断定できない肝機能異常の治療薬
AU2008247382B2 (en) * 2007-05-07 2014-06-05 Medimmune, Llc Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
EP2455396A4 (en) * 2009-07-16 2013-05-01 Otsuka Chemical Co Ltd EXTRACELLULAR AILIM DOMAIN PLACED WITH SUGAR CHAINS AND METHOD OF MANUFACTURING THE SAME
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
WO2011130322A1 (en) * 2010-04-12 2011-10-20 University Of Miami Macroporous bioengineered scaffolds for cell transplantation
EP3147297B1 (en) * 2011-03-31 2018-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos and uses thereof
US20150139994A1 (en) * 2013-11-12 2015-05-21 The Regents Of The University Of California Compositions and methods for preventing allogeneic immune rejection
EP4162947A1 (en) * 2013-11-22 2023-04-12 Takeda Pharmaceutical Company Limited Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10941446B2 (en) 2014-03-12 2021-03-09 Icahn School Of Medicine At Mount Sinai Method for identifying kidney allograft recipients at risk for chronic injury
CN113444783B (zh) 2014-06-26 2024-04-09 西奈山伊坎医学院 通过分析预示性基因集诊断亚临床和临床的急性排异的方法
ES2897004T3 (es) 2014-06-26 2022-02-28 Icahn School Med Mount Sinai Métodos para diagnosticar el riesgo de fibrosis y rechazo de aloinjerto renal
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
CN107849084B (zh) 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
PT3440076T (pt) 2016-04-07 2022-07-29 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas úteis como modeladores de proteína
KR20190003699A (ko) 2016-05-05 2019-01-09 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 제스트 인핸서 상동체 2 억제제
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US20190241573A1 (en) 2016-07-20 2019-08-08 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US20200062735A1 (en) 2017-02-27 2020-02-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
BR112019025913A2 (pt) 2017-06-09 2020-06-30 Glaxosmithkline Intellectual Property Development Limited métodos para tratar câncer em um paciente em necesssidade do mesmo e para produzir um anticorpo, anticorpo anti-icos ou fragmento de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou fragmento de ligação ao antígeno do mesmo, uso de um anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo na fabricação de um medicamento, polinucleotídeo que codifica um anticorpo, vetor, e, célula hospedeira.
JP2020522555A (ja) 2017-06-09 2020-07-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 組み合わせ療法
JP2020522556A (ja) 2017-06-09 2020-07-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌を治療するためのｉｃｏｓアゴニストおよびｏｘ４０アゴニストでの組み合わせ療法
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
EP3692066A2 (en) 2017-09-14 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer
CA3077337A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
AU2018344902B2 (en) 2017-10-05 2021-06-03 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING) useful in treating HIV
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
RU2688172C1 (ru) * 2018-04-05 2019-05-20 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ профилактики отторжения трансплантата трупной почки
CA3095198A1 (en) 2018-04-16 2019-10-24 Icahn School Of Medicine At Mount Sinai Method and kits for prediction of acute rejection and renal allograft loss using pre-transplant transcriptomic signatures in recipient blood
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
JP2021525271A (ja) 2018-05-31 2021-09-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｉｃｏｓ結合タンパク質及びアルギニンメチルトランスフェラーゼ阻害剤を用いた複合療法
US20210267973A1 (en) 2018-05-31 2021-09-02 Glaxosmithkline Intellectual Property Development Limited Combination of a type ii protein arginine methyltransferase inhibitor and an icos binding protein to treat cancer
WO2020031087A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
BR112021007517A2 (pt) 2018-10-22 2021-10-26 Glaxosmithkline Intellectual Property Development Limited Dosagem
US20200368369A1 (en) * 2019-05-22 2020-11-26 Wyvern Pharmaceuticals Inc. Composition for endogenous production of checkpoint protein precursors
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
WO2021046289A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab
WO2021058711A2 (en) 2019-09-27 2021-04-01 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
EP4077318B1 (en) 2019-12-18 2025-10-15 Ctxt Pty Ltd Benzimidazole dimers as modulators of sting
CN113294813B (zh) * 2020-02-24 2022-09-02 宁波方太厨具有限公司 一种电磁灶
AU2021256652A1 (en) 2020-04-14 2022-11-03 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer involving anti-ICOS and anti-PD1 antibodies, optionally further involving anti-tim3 antibodies
JP2023521227A (ja) 2020-04-14 2023-05-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 癌の併用療法
CA3175490A1 (en) 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Limited Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein
CA3212345A1 (en) 2021-03-02 2022-09-09 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as dnmt1 inhibitors
JP2024511831A (ja) 2021-03-31 2024-03-15 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 抗原結合タンパク質およびそれらの組み合わせ

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033770A1 (en) * 1994-06-03 1995-12-14 Repligen Corporation Ligands for induction of antigen specific apoptosis in t cells
WO1998019706A1 (en) * 1996-11-08 1998-05-14 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
WO1998038206A1 (en) * 1997-02-26 1998-09-03 Raisio Benecol Ltd. Process for the preparation of stanol esters
JPH11228442A (ja) * 1998-02-09 1999-08-24 Cypros Pharmaceut Corp 臓器移植後のシクロスポリン投与量を低減するためのフルクトース二リン酸の使用
JP2000154151A (ja) * 1998-09-14 2000-06-06 Kyo Jo 免疫抑制剤
WO2000046240A2 (en) * 1999-02-03 2000-08-10 Amgen Inc. Polypeptides involved in immune response
WO2001015732A1 (en) * 1999-08-30 2001-03-08 Japan Tobacco Inc. Remedies for immunological diseases
WO2001087981A2 (en) * 2000-05-18 2001-11-22 Japan Tobacco, Inc. Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
IL102176A (en) * 1991-06-11 2001-09-13 Blood Res Center Recombinant nucleic acid molecule capable of encoding intercellular adhesion molecule 3, functional derivatives of icam-3 and pharmaceutical compositions containing icam-3 or functional derivatives thereof
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
JP3162438B2 (ja) 1991-09-12 2001-04-25 住友製薬株式会社 高感度特異的抗体測定法
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5747461A (en) * 1994-07-26 1998-05-05 Markov; Angel K. Synergistic administration of cyclosporine and fructose diphosphate
CA2242414C (en) 1996-01-23 2012-01-03 Genentech, Inc. Anti-cd18 antibodies for use against stroke
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
NZ334714A (en) 1996-09-18 2000-08-25 Zetesis Spa Liver proteins as agents against autoimmune diseases
AU4145597A (en) 1997-02-20 1998-09-09 Cedars-Sinai Medical Center Ulcerative colitis panca secretory vesicle antigen and methods of using sa me
US7112655B1 (en) * 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
WO2001018022A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 human secreted proteins
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
CA2305350C (en) 1997-09-23 2015-04-07 Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof
AU767241B2 (en) * 1998-09-14 2003-11-06 Qiang Xu Immunosuppressive agents
EP1119253A4 (en) 1998-10-07 2005-12-21 Millennium Pharm Inc NEW SPECIFIC MOLECULES OF Th2 AND USES THEREOF
BR0010711A (pt) 1999-05-06 2002-02-13 Genetics Inst Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
AU6615500A (en) 1999-07-28 2001-02-19 Genetics Institute Inc. Preventing immune-mediated abortion by inhibiting costimulation
WO2001012658A2 (en) 1999-08-11 2001-02-22 Isis Innovations Limited Human icos ligand and application thereof
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
DK1218504T3 (da) 1999-09-21 2007-11-12 Genetics Inst Llc GL50 molekyler og anvendelser deraf
EP1224201A4 (en) 1999-10-29 2005-03-02 Human Genome Sciences Inc 32 HUMAN SECRETED PROTEINS
WO2001064704A1 (en) 2000-03-02 2001-09-07 Mayo Foundation For Medical Education And Research hB7-H2, A NOVEL CO-STIMULATORY MOLECULE
JP4236925B2 (ja) 2000-11-28 2009-03-11 アムジエン・インコーポレーテツド 免疫応答に関与する新規ポリペプチド
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033770A1 (en) * 1994-06-03 1995-12-14 Repligen Corporation Ligands for induction of antigen specific apoptosis in t cells
WO1998019706A1 (en) * 1996-11-08 1998-05-14 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
WO1998038206A1 (en) * 1997-02-26 1998-09-03 Raisio Benecol Ltd. Process for the preparation of stanol esters
JPH11228442A (ja) * 1998-02-09 1999-08-24 Cypros Pharmaceut Corp 臓器移植後のシクロスポリン投与量を低減するためのフルクトース二リン酸の使用
JP2000154151A (ja) * 1998-09-14 2000-06-06 Kyo Jo 免疫抑制剤
WO2000046240A2 (en) * 1999-02-03 2000-08-10 Amgen Inc. Polypeptides involved in immune response
WO2001015732A1 (en) * 1999-08-30 2001-03-08 Japan Tobacco Inc. Remedies for immunological diseases
WO2001087981A2 (en) * 2000-05-18 2001-11-22 Japan Tobacco, Inc. Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HUTLOFF ANDREAS: "ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28", NATURE, vol. 397, January 1999 (1999-01-01), pages 263 - 266, XP002156736 *
KENICHIRO KIYONO: "Fukushigeki no sogai no yoru kanyo yudo", IGAKU NO AYUMI, vol. 196, no. 13, 31 March 2001 (2001-03-31), pages 949 - 952, XP002955855 *
OGAWA SHU-HEI ET AL.: "Opposing effects of anti-activation-inducible lymphocyte-immunomodulatory molecule/inducible costimulator antibody on the development of acute versus chronic graft-versus-horst disease", J. IMMUNOL., vol. 167, no. 10, November 2001 (2001-11-01), pages 5741 - 5748, XP002950182 *
TAFURI ANNA ET AL.: "ICOS is essential for effective T-help er-cell responses", NATURE, vol. 409, January 2001 (2001-01-01), pages 105 - 109, XP002950181 *
YOSHINAGA STEVEN K. ET AL.: "T-cell co-stimulation through B7RP-1 and ICOS", NATURE, vol. 402, December 1999 (1999-12-01), pages 827 - 832, XP002157212 *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932358B2 (en) 1997-02-27 2011-04-26 Japan Tobacco Inc. Antibodies to JTT-1 protein and cells secreting such antibodies
US7030225B1 (en) 1997-02-27 2006-04-18 Japan Tobacco, Inc. Antibodies to JTT-1 protein, cells secreting such antibodies, and methods of making such antibodies
US7045615B2 (en) 1997-02-27 2006-05-16 Japan Tobacco, Inc. Nucleic acids encoding JTT-1 protein
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
US8389690B2 (en) 1997-02-27 2013-03-05 Japan Tobacco Inc. Antibodies to JTT-1 protein and cells secreting such antibodies
US7196175B2 (en) 1997-02-27 2007-03-27 Japan Tobacco Inc. Antibodies to JTT-1 protein and cells secreting such antibodies
US7217792B2 (en) 1997-02-27 2007-05-15 Japan Tobacco Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
US7226909B2 (en) 1997-02-27 2007-06-05 Japan Tobacco Inc. Methods of inhibiting transmission of a costimulatory signal of lymphocytes
US7247612B2 (en) 1997-02-27 2007-07-24 Japan Tobacco Inc. Methods of treating an inflammatory disease with a JJT-1 polypeptide
US7259147B2 (en) 1997-02-27 2007-08-21 Japan Tobacco Inc. Methods of treating multiple sclerosis with a JTT-1 polypeptide
US7279560B2 (en) 1997-02-27 2007-10-09 Japan Tobacco Inc. Antibody fragments to JTT-1 protein and cells secreting such antibody fragments
US7294473B2 (en) 1997-02-27 2007-11-13 Japan Tobacco Inc. Methods of identifying substances that interact with JTT-1 protein
US7465445B2 (en) 1999-08-30 2008-12-16 Japan Tobacco Inc. Methods of preventing or treating graft versus host reaction by administering an antibody or portion thereof that binds to AILIM
US7998478B2 (en) 1999-08-30 2011-08-16 Japan Tobacco, Inc. Pharmaceutical composition for treating immune diseases
US6803039B2 (en) 2000-05-18 2004-10-12 Japan Tobacco Inc. Human monoclonal antibody against a costimulatory signal transduction molecule AILIM
US7988965B2 (en) 2000-05-18 2011-08-02 Japan Tobacco, Inc. Methods of treating systemic lupus erythematosus with an antibody against costimulatory signal transduction molecule ailim
US7166283B2 (en) 2000-05-18 2007-01-23 Japan Tobacco Inc. Methods of treating an inflammatory disorder and prohibiting proliferation, cytokine production, and signal transduction with antibody against costimulatory signal transduction molecule AILIM
US7438905B2 (en) 2001-03-01 2008-10-21 Japan Tobacco, Inc. Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM
US7465444B2 (en) 2001-03-27 2008-12-16 Japan Tobacco, Inc. Methods of suppressing or treating an inflammatory bowel disease by administering an antibody or portion thereof that binds to AILIM
US8052972B2 (en) 2001-03-27 2011-11-08 Japan Tobacco, Inc. Remedies for inflammatory bowel diseases
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
WO2017220990A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
WO2019122884A1 (en) 2017-12-19 2019-06-27 Kymab Limited Antibodies to icos
WO2021229032A1 (en) 2020-05-14 2021-11-18 Kymab Limited Tumour biomarkers for immunotherapy
WO2022243378A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
WO2022254227A1 (en) 2021-06-04 2022-12-08 Kymab Limited Treatment of pd-l1 negative or low expressing cancer with anti-icos antibodies
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies
RU2833126C2 (ru) * 2022-11-15 2025-01-14 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр гематологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ гематологии" Минздрава России) Способ профилактики несостоятельности трансплантата аллогенного костного мозга или гемопоэтических стволовых клеток при наличии у реципиента донор-специфичных анти-HLA антител

Also Published As

Publication number Publication date
BR0207787A (pt) 2004-03-23
US20040253229A1 (en) 2004-12-16
HU228045B1 (en) 2012-09-28
RU2263512C2 (ru) 2005-11-10
EP1374901B1 (en) 2007-01-24
JP2003277293A (ja) 2003-10-02
DE60217839D1 (de) 2007-03-15
JP4212278B2 (ja) 2009-01-21
EP1374901A4 (en) 2004-09-15
US20090047292A1 (en) 2009-02-19
DK1769807T3 (da) 2010-07-19
KR100609444B1 (ko) 2006-08-03
NO20033839D0 (no) 2003-08-29
NO20110218L (no) 2003-11-03
NZ527076A (en) 2006-03-31
US7438905B2 (en) 2008-10-21
CN1518458B (zh) 2010-05-26
EP1769807B1 (en) 2010-04-07
NO20033839L (no) 2003-11-03
DE60235928D1 (de) 2010-05-20
IL156845A (en) 2011-10-31
HK1102293A1 (en) 2007-11-16
EP1769807A1 (en) 2007-04-04
CY1110143T1 (el) 2015-01-14
ATE463256T1 (de) 2010-04-15
NO331690B1 (no) 2012-02-27
CA2439858C (en) 2009-07-14
CA2439858A1 (en) 2002-09-12
HK1061531A1 (en) 2004-09-24
DE60217839T2 (de) 2007-11-15
MXPA03006736A (es) 2004-05-31
HUP0303332A2 (hu) 2003-12-29
CZ20032406A3 (cs) 2004-10-13
EP1374901A1 (en) 2004-01-02
SK288048B6 (sk) 2013-03-01
IL156845A0 (en) 2004-02-08
HU228108B1 (en) 2012-11-28
ATE352318T1 (de) 2007-02-15
PT1769807E (pt) 2010-06-02
RU2003129166A (ru) 2005-03-10
AU2002228435B2 (en) 2005-03-10
SI1769807T1 (sl) 2010-08-31
KR20030078946A (ko) 2003-10-08
SK12142003A3 (sk) 2004-05-04
CN1518458A (zh) 2004-08-04
ES2344219T3 (es) 2010-08-20
EP1374901B9 (en) 2007-11-07

Similar Documents

Publication Publication Date Title
WO2002070010A1 (fr) Inhibiteurs de rejet du greffon
WO2004050026A3 (en) Compositions and methods for treating prostate cancer
WO2004043293A3 (en) Cardiac valve procedure methods and devices
WO2004043374A3 (en) Methods and compositions for treating cancer using proteasome inhibitors
WO2007089577A3 (en) Method of reversing, preventing, delaying or stabilizing soft tissue calcification
WO2004039248A3 (en) Repairing or replacing tissues or organs
MY137250A (en) Method of treatment of transplant rejection
WO2006042100A3 (en) Method for the treatment of polycystic kidney disease
EP1751272B8 (en) Production of tacrolimus (fk-506) using new streptomyces species
Roque et al. Preoperative drainage for malignant biliary strictures: is it time for self-expanding metallic stents?
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
WO2005110479A3 (en) Treatments for pancreatic cancer
WO2004052305A3 (en) Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
WO2006077592A3 (en) Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
ATE335475T1 (de) Verwendung von beschleunigten lymphozyten zielansteuernden wirkstoffen zur herstellung eines medikaments für die behandlung der verzögertern transplantat-funktion
WO2005041877A3 (en) Method of inhibiting rejection following organ transplantation
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
WO2005058243A3 (en) Methods for treating cancer using vascular endothelial cell growth inhibitor vegi-192a
DE60117762D1 (de) Vitamin d-verbindungen zur behandlung von chronischer tranplantatnephropathie bei nieren transplantieren patienten
WO2001045680A3 (en) Cd45 inhibitors
NO20016316L (no) Fremgangsmåte til å behandle eller forhindre kransarterietransplantasjonsvasospasme
WO2004075977A3 (en) Methods using diffuse field ultrasound-induced hyperthermia
WO2003039231A3 (en) Compounds and methods for treating transplant rejection
WO2001096398A3 (en) Uncoupling proteins as targets for the treatment of heart failure
UA37741A (uk) Спосіб профілактики післяопераційного панкреатиту при холецистектомії

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 156845

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002228435

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 527076

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/006736

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003/06516

Country of ref document: ZA

Ref document number: 200306516

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020037011255

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 028058054

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2439858

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PV2003-2406

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 12142003

Country of ref document: SK

Ref document number: 1538/CHENP/2003

Country of ref document: IN

Ref document number: 1200300859

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 2002710508

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037011255

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2002710508

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-2406

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2002228435

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 527076

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002710508

Country of ref document: EP